Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease

Han Hyo Lee, Yeon Seok Seo, Soon-Ho Um, Nam Hee Won, Hanna Yoo, Eun Suk Jung, Yong Dae Kwon, Sanghoon Park, Bora Keum, Yong Sik Kim, Hyung Joon Yim, Yoon Tae Jeen, Hoon-Jai Chun, Chang Duck Kim, Ho Sang Ryu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The purpose of this prospective study was to verify and compare the strengths of various blood markers and fibrosis models in predicting significant liver fibrosis. One hundred fifty-eight patients with chronic liver disease who underwent liver biopsy were enrolled. The mean age was 41 yr and male patients accounted for 70.2%. The common causes of liver disease were hepatitis B (67.7%) and C (16.5%) and fatty liver (9.5%). Stages of liver fibrosis (F0-4) were assessed according to the Batts and Ludwig scoring system. Significant fibrosis was defined as ≥F2. Sixteen blood markers were measured along with liver biopsy, and estimates of hepatic fibrosis were calculated using various predictive models. Predictive accuracy was evaluated with a receiver-operating characteristics (ROC) curve. Liver biopsy revealed significant fibrosis in 106 cases (67.1%). On multivariate analysis, α2-macroglobulin, hyaluronic acid, and haptoglobin were found to be independently related to significant hepatic fibrosis. A new predictive model was constructed based on these variables, and its area under the ROC curve was 0.91 (95% confidence interval, 0.85-0.96). In conclusion, α2-macroglobulin, hyaluronic acid, and haptoglobin levels are independent predictors for significant hepatic fibrosis in chronic liver disease.

Original languageEnglish
Pages (from-to)67-74
Number of pages8
JournalJournal of Korean Medical Science
Volume25
Issue number1
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

Liver Diseases
Fibrosis
Chronic Disease
Liver
Macroglobulins
Haptoglobins
Hyaluronic Acid
Biopsy
ROC Curve
Liver Cirrhosis
Fatty Liver
Hepatitis C
Hepatitis B
Multivariate Analysis
Prospective Studies
Confidence Intervals

Keywords

  • Biological markers
  • Chronic liver disease
  • Liver cirrhosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease. / Lee, Han Hyo; Seo, Yeon Seok; Um, Soon-Ho; Won, Nam Hee; Yoo, Hanna; Jung, Eun Suk; Kwon, Yong Dae; Park, Sanghoon; Keum, Bora; Kim, Yong Sik; Yim, Hyung Joon; Jeen, Yoon Tae; Chun, Hoon-Jai; Kim, Chang Duck; Ryu, Ho Sang.

In: Journal of Korean Medical Science, Vol. 25, No. 1, 01.01.2010, p. 67-74.

Research output: Contribution to journalArticle

@article{e0b2d3131bcd496994034c679594034b,
title = "Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease",
abstract = "The purpose of this prospective study was to verify and compare the strengths of various blood markers and fibrosis models in predicting significant liver fibrosis. One hundred fifty-eight patients with chronic liver disease who underwent liver biopsy were enrolled. The mean age was 41 yr and male patients accounted for 70.2{\%}. The common causes of liver disease were hepatitis B (67.7{\%}) and C (16.5{\%}) and fatty liver (9.5{\%}). Stages of liver fibrosis (F0-4) were assessed according to the Batts and Ludwig scoring system. Significant fibrosis was defined as ≥F2. Sixteen blood markers were measured along with liver biopsy, and estimates of hepatic fibrosis were calculated using various predictive models. Predictive accuracy was evaluated with a receiver-operating characteristics (ROC) curve. Liver biopsy revealed significant fibrosis in 106 cases (67.1{\%}). On multivariate analysis, α2-macroglobulin, hyaluronic acid, and haptoglobin were found to be independently related to significant hepatic fibrosis. A new predictive model was constructed based on these variables, and its area under the ROC curve was 0.91 (95{\%} confidence interval, 0.85-0.96). In conclusion, α2-macroglobulin, hyaluronic acid, and haptoglobin levels are independent predictors for significant hepatic fibrosis in chronic liver disease.",
keywords = "Biological markers, Chronic liver disease, Liver cirrhosis",
author = "Lee, {Han Hyo} and Seo, {Yeon Seok} and Soon-Ho Um and Won, {Nam Hee} and Hanna Yoo and Jung, {Eun Suk} and Kwon, {Yong Dae} and Sanghoon Park and Bora Keum and Kim, {Yong Sik} and Yim, {Hyung Joon} and Jeen, {Yoon Tae} and Hoon-Jai Chun and Kim, {Chang Duck} and Ryu, {Ho Sang}",
year = "2010",
month = "1",
day = "1",
doi = "10.3346/jkms.2010.25.1.67",
language = "English",
volume = "25",
pages = "67--74",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "1",

}

TY - JOUR

T1 - Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease

AU - Lee, Han Hyo

AU - Seo, Yeon Seok

AU - Um, Soon-Ho

AU - Won, Nam Hee

AU - Yoo, Hanna

AU - Jung, Eun Suk

AU - Kwon, Yong Dae

AU - Park, Sanghoon

AU - Keum, Bora

AU - Kim, Yong Sik

AU - Yim, Hyung Joon

AU - Jeen, Yoon Tae

AU - Chun, Hoon-Jai

AU - Kim, Chang Duck

AU - Ryu, Ho Sang

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The purpose of this prospective study was to verify and compare the strengths of various blood markers and fibrosis models in predicting significant liver fibrosis. One hundred fifty-eight patients with chronic liver disease who underwent liver biopsy were enrolled. The mean age was 41 yr and male patients accounted for 70.2%. The common causes of liver disease were hepatitis B (67.7%) and C (16.5%) and fatty liver (9.5%). Stages of liver fibrosis (F0-4) were assessed according to the Batts and Ludwig scoring system. Significant fibrosis was defined as ≥F2. Sixteen blood markers were measured along with liver biopsy, and estimates of hepatic fibrosis were calculated using various predictive models. Predictive accuracy was evaluated with a receiver-operating characteristics (ROC) curve. Liver biopsy revealed significant fibrosis in 106 cases (67.1%). On multivariate analysis, α2-macroglobulin, hyaluronic acid, and haptoglobin were found to be independently related to significant hepatic fibrosis. A new predictive model was constructed based on these variables, and its area under the ROC curve was 0.91 (95% confidence interval, 0.85-0.96). In conclusion, α2-macroglobulin, hyaluronic acid, and haptoglobin levels are independent predictors for significant hepatic fibrosis in chronic liver disease.

AB - The purpose of this prospective study was to verify and compare the strengths of various blood markers and fibrosis models in predicting significant liver fibrosis. One hundred fifty-eight patients with chronic liver disease who underwent liver biopsy were enrolled. The mean age was 41 yr and male patients accounted for 70.2%. The common causes of liver disease were hepatitis B (67.7%) and C (16.5%) and fatty liver (9.5%). Stages of liver fibrosis (F0-4) were assessed according to the Batts and Ludwig scoring system. Significant fibrosis was defined as ≥F2. Sixteen blood markers were measured along with liver biopsy, and estimates of hepatic fibrosis were calculated using various predictive models. Predictive accuracy was evaluated with a receiver-operating characteristics (ROC) curve. Liver biopsy revealed significant fibrosis in 106 cases (67.1%). On multivariate analysis, α2-macroglobulin, hyaluronic acid, and haptoglobin were found to be independently related to significant hepatic fibrosis. A new predictive model was constructed based on these variables, and its area under the ROC curve was 0.91 (95% confidence interval, 0.85-0.96). In conclusion, α2-macroglobulin, hyaluronic acid, and haptoglobin levels are independent predictors for significant hepatic fibrosis in chronic liver disease.

KW - Biological markers

KW - Chronic liver disease

KW - Liver cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=77949330366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949330366&partnerID=8YFLogxK

U2 - 10.3346/jkms.2010.25.1.67

DO - 10.3346/jkms.2010.25.1.67

M3 - Article

C2 - 20052350

AN - SCOPUS:77949330366

VL - 25

SP - 67

EP - 74

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 1

ER -